News | September 17, 2010

German Company Reports First-in-Man Transcatheter Aortic Valve


September 17, 2010 - An aortic valve has been successfully implanted in the acute porcine model by Transcatheter Technologies GmbH (TT) using its Trinity system.

The acute in vivo study of the system has shown:

• Accurate stepwise positioning of Trinity via an antegrade transapical approach.
• Full expansion and anchoring of the Trinity valve prosthesis before the refolding of the stent.
• Complete evaluation of the fully expanded prosthesis’ function before refolding and repositioning or retrieval.
• Detachment of the stent from the catheter without changing the geometry of the deployed valve prosthesis.
• Outstanding anchoring and sealing due to the design of the stent.
• Low transvalvular gradients.

TT’s true repositioning system allows for complete expansion of the valved stent and full evaluation of prosthesis' function before repositioning, before retrieval and before final release.

“Trinity protects the fragile valve leaflets by Zero Pressure Crimping. This prevents crushing and damaging of the leaflets when the frame is folded. We expect that this will increase the lifespan of the valve prosthesis and thereby allow for implantation in even younger patients,” commented Wolfgang Goetz, M.D., Ph.D., CEO. “Our animal trials validate the feasibility of the technology in vivo. We are very proud to have achieved this significant milestone within a very short period of time.”

Transcatheter Technologies successfully closed the seed financing round in 2009 with High-Tech Gründerfonds and Seedfonds Bayern. The investment will be used for the development of a novel biological heart valve up to the proof of concept.

“Transcatheter Technologies’ valve design can solve major problems of common prosthesis. Thereby, valve implantations become an option for currently untreatable patients,” said Dr. Michael Nettersheim, of High-Tech Gründerfonds. “We are convinced that the medicinal as well as technological expertise of the team provide an ideal base for a successful corporate development.”

For more information: www.high-tech-gruenderfonds.de


Related Content

News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
News | Heart Valve Technology

Jan. 6, 2025 — Medtronic plc has announced it received CE (Conformité Européenne) Mark for the Harmony Transcatheter ...

Home January 06, 2025
Home
News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
Subscribe Now